In addition, the present study comprehensively evaluated survival outcomes (including PFS and OS), response to treatment (containing ORR and DCR), and AEs between Osimertinib and EGFR-TKIs/chemotherapy in advanced NSCLC patients with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.